200 related articles for article (PubMed ID: 29987919)
1. N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
Idzerda NMA; Persson F; Pena MJ; Brenner BM; Brunel P; Chaturvedi N; McMurray JJ; Parving HH; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Dec; 20(12):2899-2904. PubMed ID: 29987919
[TBL] [Abstract][Full Text] [Related]
2. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
Smink PA; Hoekman J; Grobbee DE; Eijkemans MJ; Parving HH; Persson F; Ibsen H; Lindholm L; Wachtell K; de Zeeuw D; Heerspink HJ
Eur J Prev Cardiol; 2014 Apr; 21(4):434-41. PubMed ID: 23467676
[TBL] [Abstract][Full Text] [Related]
3. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
Malachias MVB; Jhund PS; Claggett BL; Wijkman MO; Bentley-Lewis R; Chaturvedi N; Desai AS; Haffner SM; Parving HH; Prescott MF; Solomon SD; De Zeeuw D; McMurray JJV; Pfeffer MA
J Am Heart Assoc; 2020 Oct; 9(19):e017462. PubMed ID: 32964800
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
6. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
7. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
[TBL] [Abstract][Full Text] [Related]
8. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
[TBL] [Abstract][Full Text] [Related]
9. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
[TBL] [Abstract][Full Text] [Related]
10. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.
Greene SJ; Fonarow GC; Solomon SD; Subacius HP; Ambrosy AP; Vaduganathan M; Maggioni AP; Böhm M; Lewis EF; Zannad F; Butler J; Gheorghiade M;
Eur J Heart Fail; 2017 Apr; 19(4):552-562. PubMed ID: 27748006
[TBL] [Abstract][Full Text] [Related]
11. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.
Price AH; Welsh P; Weir CJ; Feinkohl I; Robertson CM; Morling JR; McLachlan S; Strachan MW; Sattar N; Price JF
Diabetologia; 2014 Dec; 57(12):2505-12. PubMed ID: 25231020
[TBL] [Abstract][Full Text] [Related]
12. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
[TBL] [Abstract][Full Text] [Related]
13. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Nicolaides M; Richard A; Xiang Z; Armbrecht J; Pfeffer MA;
J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):387-93. PubMed ID: 22333485
[TBL] [Abstract][Full Text] [Related]
15. Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
Said F; Arnott C; Voors AA; Heerspink HJL; Ter Maaten JM
Diabetes Obes Metab; 2024 Jul; 26(7):2741-2751. PubMed ID: 38584567
[TBL] [Abstract][Full Text] [Related]
16. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
[TBL] [Abstract][Full Text] [Related]
17. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.
Maggioni AP; Greene SJ; Fonarow GC; Böhm M; Zannad F; Solomon SD; Lewis EF; Baschiera F; Hua TA; Gimpelewicz CR; Lesogor A; Gheorghiade M;
Eur Heart J; 2013 Oct; 34(40):3117-27. PubMed ID: 23999456
[TBL] [Abstract][Full Text] [Related]
18. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.
Srivastava PK; Pradhan AD; Cook NR; Ridker PM; Everett BM
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29275373
[TBL] [Abstract][Full Text] [Related]
20. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.
Tarnow L; Gall MA; Hansen BV; Hovind P; Parving HH
Diabetologia; 2006 Oct; 49(10):2256-62. PubMed ID: 16937127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
